Uveitis

Uveitis is inflammation of the uvea, the middle layer of the eye that supplies blood to the retina. It is one of the leading causes of preventable blindness in working-age adults worldwide. Unlike many eye conditions that develop slowly over decades, uveitis can flare suddenly and damage vision within days if not treated. Understanding what it is, what triggers it, and how it is managed can make a real difference in protecting your sight.

Table of Contents

  1. Overview and Definition
  2. Types of Uveitis
  3. Causes and Risk Factors
  4. Symptoms
  5. Diagnosis
  6. Conventional Treatment
  7. Natural and Lifestyle Approaches
  8. Complications
  9. Prognosis
  10. Prevention
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Overview and Definition

The eye is often described as a layered sphere. The outermost layer is the tough white sclera and the clear cornea. The innermost layer is the light-sensing retina. Sandwiched between them is the uvea, a richly vascular, pigmented middle coat made up of three connected structures:

When any part of this middle coat becomes inflamed — whether from an infection, an autoimmune response, or an injury — the condition is called uveitis. The inflammation can be confined to one part of the uvea or spread across the entire structure.

Uveitis affects an estimated 2 to 5 million people in the United States and accounts for roughly 10 to 15 percent of cases of legal blindness in the developed world. It strikes people of all ages but peaks in adults between 20 and 60 — the prime of working and family life. Because the uvea is so vascular, inflammation there can rapidly spill over to damage the lens, retina, optic nerve, and fluid-drainage system of the eye.

Back to Table of Contents

Types of Uveitis

Ophthalmologists classify uveitis by where in the eye the inflammation is located. This anatomical classification matters enormously because the underlying causes, treatments, and risks of complications differ by type.

Anterior Uveitis (Iritis / Iridocyclitis)

Anterior uveitis affects the iris and ciliary body — the front chamber of the eye. It is by far the most common form, accounting for roughly 50 to 90 percent of all uveitis cases in most clinical series. Most anterior uveitis is unilateral (one eye at a time), acute (comes on suddenly), and responds well to steroid eye drops. Chronic forms are rarer but more sight-threatening. The term iritis refers specifically to isolated iris inflammation; iridocyclitis means both iris and ciliary body are involved.

Intermediate Uveitis (Pars Planitis)

Intermediate uveitis centers on the vitreous — the gel-filled cavity behind the lens — and the peripheral retina and pars plana (the flat part of the ciliary body). Patients typically notice floaters and blurry vision. Pain and redness are often mild or absent. It is associated with conditions such as multiple sclerosis and sarcoidosis, but in many young patients no systemic cause is found (idiopathic pars planitis).

Posterior Uveitis (Chorioretinitis)

Posterior uveitis involves the choroid and/or retina at the back of the eye. Because there are no pain receptors in the retina, patients may have surprisingly little discomfort even while the inflammation silently damages their central vision. Infectious causes — particularly toxoplasmosis and cytomegalovirus — are common. Posterior uveitis carries the highest risk of permanent vision loss.

Panuveitis

Panuveitis is inflammation involving all three anatomical segments simultaneously. It is the most severe form and is associated with systemic diseases such as sarcoidosis, Behcet disease, and Vogt-Koyanagi-Harada (VKH) syndrome. Vision-threatening complications are the rule rather than the exception without aggressive treatment.

Back to Table of Contents

Causes and Risk Factors

Identifying the cause of uveitis is one of the most important — and sometimes most challenging — tasks in management. About 30 to 50 percent of cases are idiopathic (no identifiable cause is found even after a thorough work-up). The remainder split broadly between infectious and non-infectious (autoimmune or immune-mediated) origins.

Infectious Causes

Non-Infectious / Autoimmune Causes

Risk Factors

Back to Table of Contents

Symptoms

Symptoms vary considerably depending on which part of the eye is inflamed. This is one of the reasons uveitis can be missed — not all forms cause the classic painful red eye.

Anterior Uveitis — Typical Symptoms

Intermediate and Posterior Uveitis — Often Subtler

When to See a Doctor Immediately

Any sudden onset of eye pain, marked redness, or rapid vision change warrants same-day evaluation by an eye doctor. Uveitis that is left untreated for even a few days can cause scarring that is difficult or impossible to reverse. Do not wait to see if it "clears up on its own."

Back to Table of Contents

Diagnosis

Uveitis is diagnosed primarily through a slit-lamp examination — a biomicroscope that allows the ophthalmologist to examine the eye's structures in exquisite detail under high magnification. No blood test or scan can replace this hands-on exam.

Slit-Lamp Examination

Intraocular Pressure (IOP)

IOP is measured at every visit. Uveitis can either raise IOP (by blocking fluid drainage with inflammatory debris or steroids) or lower it (severely inflamed ciliary bodies produce less fluid). Both extremes are important to track.

Dilated Fundus Examination

After dilating the pupils with drops, the ophthalmologist examines the vitreous, retina, choroid, and optic nerve with indirect ophthalmoscopy and contact lenses. This is the only way to detect posterior uveitis, retinal vasculitis, choroidal granulomas, or early signs of macular edema.

Imaging Studies

Systemic Work-Up

Finding the underlying cause guides treatment. The extent of the work-up depends on the clinical picture — a young adult with a first episode of acute anterior uveitis after a GI illness may only need HLA-B27 testing, while a patient with bilateral granulomatous posterior uveitis needs a much broader panel.

Back to Table of Contents

Conventional Treatment

The goals of treatment are to suppress inflammation, prevent damage, preserve vision, and treat any underlying systemic disease. Therapy is tailored to the type, severity, and cause of uveitis.

Corticosteroids — The Foundation of Treatment

Corticosteroids remain the first-line anti-inflammatory agents for most non-infectious uveitis. They are used in several forms:

Mydriatics and Cycloplegics

Drops such as atropine, cyclopentolate, or tropicamide dilate the pupil and paralyze the ciliary muscle. This accomplishes two things: it relieves the spasm-driven pain of anterior uveitis, and it prevents the iris from sticking to the lens. These drops are typically used for the first few weeks of an acute anterior uveitis episode.

Steroid-Sparing Immunosuppressants

When uveitis is chronic, recurrent, or posterior, long-term systemic immunosuppression is often necessary to control the disease while minimizing steroid exposure. The main agents are:

Biologic Therapies

Adalimumab (Humira), a TNF-alpha inhibitor, became the first biologic approved by the FDA specifically for non-infectious intermediate, posterior, and panuveitis in adults who have failed conventional immunosuppression. The pivotal VISUAL I and VISUAL II trials demonstrated that adalimumab significantly reduced the risk of uveitis flares and vision-threatening complications compared to placebo. Infliximab, another TNF inhibitor, is used off-label, particularly for Behcet disease where the evidence base is strong. Other biologics being evaluated include secukinumab (anti-IL-17) and tocilizumab (anti-IL-6).

Anti-Infective Therapy

Infectious uveitis requires targeted treatment of the causative organism:

Back to Table of Contents

Natural and Lifestyle Approaches

Natural approaches do not replace medical treatment for active uveitis — this is an inflammatory condition that can cause permanent blindness without proper management. However, evidence supports several complementary strategies that may reduce the frequency and severity of flares and support overall eye health.

Omega-3 Fatty Acids

Omega-3 polyunsaturated fatty acids — particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — competitively inhibit the production of pro-inflammatory prostaglandins and cytokines. Studies in inflammatory eye diseases suggest that higher omega-3 intake is associated with reduced inflammation markers. Fatty fish (salmon, sardines, mackerel, herring), walnuts, and flaxseed are the richest food sources. A daily supplement of 2–3 grams of combined EPA+DHA is generally safe, though it may interact with anticoagulants.

Vitamin D

Vitamin D deficiency is remarkably common and has been associated with an increased risk of autoimmune conditions including the inflammatory arthropathies that cause HLA-B27-related uveitis. Vitamin D acts as an immune modulator, promoting regulatory T-cell activity that helps prevent excessive immune responses. Getting adequate sunlight exposure, eating vitamin D-rich foods (fatty fish, eggs), and supplementing to maintain a serum 25-OH vitamin D level above 40–60 ng/mL is a reasonable general strategy for people with recurrent immune-mediated uveitis.

Antioxidant-Rich Diet

Dark leafy greens (spinach, kale, collard greens) are rich in lutein and zeaxanthin — xanthophyll carotenoids concentrated in the macula that filter damaging blue light and act as local antioxidants. While research on lutein specifically in uveitis is limited, the broader anti-inflammatory dietary pattern (Mediterranean-style, high in vegetables, fruit, whole grains, olive oil, and fish) is associated with lower systemic inflammatory markers and better outcomes in immune-mediated diseases.

Avoiding Smoking

Tobacco smoking significantly worsens outcomes in inflammatory eye diseases. It promotes systemic oxidative stress and inflammation, impairs the response to immunosuppressive medications, and independently increases the risk of macular degeneration and cataract — two of uveitis's most dangerous complications. Quitting smoking is one of the highest-value lifestyle changes a uveitis patient can make.

Stress Management

Psychological stress reliably triggers flares of autoimmune and inflammatory conditions. Mechanisms include stress-hormone-driven shifts in immune regulation (cortisol initially suppresses inflammation, but chronic stress dysregulates the HPA axis and ultimately promotes it). Mind-body practices with a reasonable evidence base include mindfulness-based stress reduction (MBSR), yoga, regular aerobic exercise, and adequate sleep. None of these is a replacement for medication, but they may extend remission intervals.

Regular Ophthalmology Follow-Up

For patients with conditions known to cause uveitis — particularly JIA in children and HLA-B27-positive spondyloarthropathies in adults — scheduled screening visits allow subclinical inflammation to be caught and treated before it causes damage. The frequency depends on the specific condition and risk profile; your ophthalmologist will set the schedule.

Back to Table of Contents

Complications

Uveitis is dangerous not only because of the inflammation itself but because of the secondary structural damage it can cause over time. These complications are the primary reason uveitis is one of the leading causes of preventable vision loss.

Cystoid Macular Edema (CME)

CME is the accumulation of fluid in the central retina (macula), disrupting the precise photoreceptor architecture needed for sharp central vision. It is the most common vision-threatening complication of uveitis, occurring in up to 40 percent of patients with intermediate or posterior uveitis. Symptoms are blurring and distortion of central vision. OCT is the gold standard for detection. Treatment involves local and systemic steroids, intravitreal anti-VEGF agents, and controlling the underlying uveitis.

Glaucoma

Uveitic glaucoma affects approximately 20 percent of uveitis patients over their lifetime. Inflammation raises IOP through multiple mechanisms: inflammatory cells clog the trabecular meshwork that drains aqueous humor; posterior synechiae can block fluid flow from the posterior to anterior chamber (causing iris bombe, a dramatic forward bowing of the iris); and long-term topical and systemic steroid use independently elevates IOP in genetically susceptible individuals ("steroid responders"). Uveitic glaucoma can be very difficult to control and may ultimately require filtering surgery or drainage implants.

Cataracts

Both uveitis and its treatment cause cataracts. Chronic inflammation directly damages the lens epithelium; corticosteroids — both topical and systemic — promote formation of posterior subcapsular cataracts, which selectively blur vision and cause severe glare. Cataract surgery in a uveitic eye is more complex and has higher complication rates than routine cataract surgery; inflammation must be fully suppressed for at least three months before operating.

Posterior Synechiae and Seclusio Pupillae

Posterior synechiae are adhesions between the posterior iris surface and the anterior lens capsule. When they encircle the entire pupil (360-degree synechiae), they create a closed ring called seclusio pupillae, which completely blocks aqueous flow and causes acute angle-closure glaucoma with rapidly rising IOP. This is a medical emergency requiring urgent laser iridotomy.

Retinal Detachment

Chronic inflammation can cause membranes to form on the surface of the retina (epiretinal membranes) or within the vitreous. These membranes can contract and pull the retina away from the underlying pigment epithelium, causing tractional or rhegmatogenous retinal detachment. Prompt surgical repair is required to preserve vision.

Hypotony

Severe, chronic inflammation of the ciliary body can so thoroughly damage its secretory function that aqueous humor production falls critically low (IOP below 6 mmHg). Sustained hypotony leads to choroidal effusions, macular folds, and eventually a shrunken, non-functional eye (phthisis bulbi). This is one of the most feared end-stage complications of untreated uveitis.

Band Keratopathy

Calcium deposits in the superficial cornea, forming a chalky white horizontal band across the visual axis, can develop in longstanding uveitis particularly in children with JIA. It can be removed with EDTA chelation treatment but tends to recur if inflammation is not controlled.

Back to Table of Contents

Prognosis

The outlook for uveitis varies enormously depending on the type, cause, and how promptly treatment begins.

Anterior Uveitis

Acute anterior uveitis (iritis) typically responds quickly to topical steroids and cycloplegics. Most episodes resolve fully within 6–8 weeks with appropriate treatment. Vision generally returns to baseline, and structural complications are uncommon in a first episode. However, recurrences are frequent — up to 50 percent of patients experience at least one additional episode within five years, particularly those who are HLA-B27-positive. Chronic anterior uveitis (as in JIA) is harder to manage and carries higher complication rates.

Intermediate Uveitis

The course tends to be protracted, with chronic smoldering inflammation punctuated by flares. CME is the main cause of vision loss. With proper immunosuppression, many patients maintain useful vision, but the disease often requires treatment for years or even decades.

Posterior and Panuveitis

These carry the highest risk of permanent vision impairment. Infectious posterior uveitis (toxoplasmosis) leaves chorioretinal scars at the site of active lesions; while subsequent episodes can be treated, each leaves additional scar tissue. VKH syndrome, Behcet disease, and severe sarcoidosis can devastate vision despite aggressive therapy, though early and sustained immunosuppression significantly improves outcomes. Overall, studies suggest that approximately 35 percent of uveitis patients have some degree of visual impairment over their disease course, with 5 to 10 percent reaching legal blindness.

Prognostic Factors

Back to Table of Contents

Prevention

Because many causes of uveitis are infectious or autoimmune — conditions not fully preventable — the emphasis in prevention is on reducing flare frequency, catching recurrences early, and preventing complications.

Back to Table of Contents

Key Research Papers

  1. Jabs et al., 2014 — Standardization of Uveitis Nomenclature for Reporting Clinical Data — PMID: 25059232
  2. Levy-Clarke et al., 2014 — Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders — PMID: 29853358
  3. Rosenbaum et al., 2016 — New Observations and Emerging Ideas in Diagnosis and Management of Non-Infectious Uveitis — PMID: 27795396
  4. Nussenblatt RB — Uveitis: Fundamentals and Clinical Practice (review) — PMID: 31071195
  5. Durrani et al. — Immunosuppression for Uveitis: A Survey of Current Treatments and Future Directions — PMID: 26457472
  6. Thorne et al., 2013 — Epidemiology of Uveitis in an Insured Population — PMID: 22944025
  7. Dick et al. — Adalimumab in Active Noninfectious Posterior Uveitis (VISUAL I and VISUAL II Trials Analysis) — PMID: 34257088
  8. Tomkins-Netzer et al. — The Natural History of Uveitis — PMID: 30352765
  9. Nguyen et al. — Biologic Therapy for Ocular Inflammation — PMID: 28399381
  10. Siddique et al. — The Clinical Features and Outcomes of Anterior Uveitis — PMID: 24877733

Back to Table of Contents

Connections

Back to Table of Contents